key: cord-0879381-div2pg0m authors: Xu, Qingyong; Sood, Puneet; Helmick, Dennis; Lomago, Jon S.; Tevar, Amit D.; Zeevi, Adriana title: Positive flow cytometry crossmatch with discrepant antibody testing results following COVID‐19 vaccination date: 2021-07-19 journal: Am J Transplant DOI: 10.1111/ajt.16753 sha: ca8d53430f403067cfde37d491d1d2b5d253465d doc_id: 879381 cord_uid: div2pg0m The impact of COVID‐19 vaccination on the alloimmunity of transplant candidates is unknown. We report a case of positive B cell flow cytometry crossmatch in a patient waiting for second kidney transplantation, 37 days after receiving the COVID‐19 vaccine. The preliminary crossmatch, using sample collected before COVID‐19 vaccination, was negative. The antibodies to mismatched donor HLA‐DR7 were detected only with multi‐antigen beads but not with single‐antigen beads, excluding possible prozone effects in solid‐phase antibody assays. The crossmatches were positive with HLA‐DR7–positive surrogates (n = 2) while negative with HLA‐DR7–negative surrogates (n = 3), which confirms the HLA‐DR7 alloreactivity. The antigen configurations on B lymphocytes are similar to that on the multi‐antigen beads while distinct from the single‐antigen beads. HLA‐DR7 was the repeating mismatched antigen with the failing first kidney allograft. The newly emerged antibody to HLA‐DR7 probably is the consequence of bystander activation of memory response by the COVID‐19 vaccination. This case highlights the importance of verifying allo‐sensitization history and utilizing multiple assays, including cell‐based crossmatch and solid‐phase assays with multi‐antigens. COVID‐19 immunization may deserve special attention when assessing the immunological risk before and after organ transplantation. detectable with the sensitive solid-phase single-antigen beads (SAB) assay. A 53-year-old male patient with end-stage renal disease secondary to membranoproliferative glomerulonephritis received a kidney transplant from a deceased donor in 1994. Due to recent biopsy-proven advanced interstitial fibrosis and tubular atrophy, his first allograft was failing (serum creatinine = 5.1 mg/dL and estimated glomerular filtration rate = 12 ml/min/1.73 m 2 ). He was evaluated for preemptive retransplantation from a related living donor (nephew). The patient has been maintained on stable triple immunosuppression of cyclosporine, azathioprine, and prednisone without recent modifications. Recently, there were no significant medical or surgical events, such as hospitalizations or blood product administrations. The patient's HLA typing is A*02:01, 24 were identified with the SAB assay ( Figure 1B ). The mean fluorescence intensity (MFI) for these positive beads ranged from 6055 to 16399. The antibody profiles were concordant in SABs and multiantigen beads and were also consistent with two historical sera collected 5 and 10 months before. These HLA-DP shared an epitope 69E (glutamic acid), which is known to be involved in peptide binding and T cell receptor recognition. 5 Noteworthily, donor-mismatched antigen HLA-DPB1*03:01 has lysine (K) at amino acid position 69 instead and was negative in SAB assay. The initial FCXM with the living donor candidate was negative for both T and B cells (Table 1) . These results were concordant with a lack of DSA in the patient's serum. One hundred and sixty-seven days after the initial FCXM, a final FCXM was performed using a fresh serum sample from the patient (designated as the second serum). Although T cell FCXM was Figure 1D ). Therefore, it appeared that the B-FCXM was positive in the absence of DSA detected with the sensitive SAB assay. However, class II PRA was increased to 37% from 20% in multi-antigen PRA beads on Luminex platform with a new pronounced HLA-DR7 pattern ( Figure 1C ). With another multi-antigen PRA beads on flow platform (One Lambda), the class II PRA also increased from 14% to 29% (data not shown). This HLA-DR7 pattern in PRA beads was absent in the first serum used in the initial crossmatch ( Figure 1A ) and two additional historical sera. HLA-DR7 was identified as the mismatched antigen with the living donor candidate. Thus, the positive B cell FCXM was supported by the presence of HLA-DR7 DSA identified with multi-antigen PRA beads but not with SAB. Were there any prozone or interference agents that covered the HLA-DR7 antibodies in the SAB assay? In our laboratory, sera are routinely treated with ethylenediaminetetraacetic acid (EDTA) to remove prozone caused by possible complement complexes. 6 To exclude any EDTA-independent prozone effects, we performed additional dilutions of the EDTA-treated sera (1:4 and 1:16) and did not find any new reactivity. In addition, the removal of IgM by heat inactivation (63℃) did not uncover any new antibodies. No DSA was found in the Luminex-based C1q assay (One Lambda) or a SAB assay from an alternative vendor (Immucor). We also tested the postvaccination serum with a new Reflex bead assay (One Lambda), coated with rather native HLA class II single antigens. The profile was similar to the regular SAB, and MFI for the DR7 bead was only 373 ( Figure 1E ). DSA at such a level usually is considered negative and incapable of causing the strong positive B cell FCXM. To better characterize the allo-specificity of the positive FCXM we observed, we tested both sera with five third-party surrogate donor cells (Table 1) . Three surrogates (#1-3) were negative for HLA-DR7, while two other donors (#4 and #5) expressed HLA-DR7. There were no DSA to HLA-DP for any of the five surrogate donors (Table S1B) in cell lines. HLA-DR is an alpha/beta heterodimer that requires a chaperon, class II-associated invariant chain peptide (CLIP) for antigen presentation and structural stability. 16 One hypothesis is that the cell lines producing the single antigens lack CLIP, while the cell lines generating the multi-antigens as well as human B cells used in FCXM have CLIP. 17, 18 In a case of a false-negative antibody to HLA-DRB5*01:01 with standard SAB assay, the antibody was detectable when single-antigen cell lines were transfected with CLIP. 17 Similarly, in this case, HLA-DR7 on SAB may have an altered configuration that may not be recognized by the HLA-DR7 antibodies. The manufacturer recently produced new Reflex beads conjugated with HLA class II antigen expressed in a CLIP-positive cell line. 18 The Reflex beads appeared to be more sensitive than regular SAB beads in detecting anti-DR7 antibodies. However, the strength (MFI = 373, Figure 1E ) was not comparable to the strong reactivity in multi-antigen beads and strong positive B cell FCXM. Alternatively, the peptides bound to HLA were reported to have an impact on the specificity of anti-HLA antibodies. 19 Possibly, the HLA-DR7 antibody recognized the HLA-DR7/peptide complex. The difference of peptide repertoire in the SAB cell lines vs. PRA bead cell lines and normal lymphocytes may explain the different reactivities of HLA-DR7 antibodies in our case. The SAB assay is routinely used in histocompatibility laboratories to determine unacceptable antigens for virtual crossmatch. 20 The pros and cons for virtual vs. cell-based crossmatches were summarized in a recent viewpoint paper. 21 The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. AJT XU et al. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. https://orcid.org/0000-0003-0579-1924 Puneet Sood https://orcid.org/0000-0002-0503-4707 Effects of influenza immunization on humoral and cellular alloreactivity in humans Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules Influenza Vaccination in the Organ Transplant Recipient: Review and Summary Recommendations † De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients The role of HLA-DP beta residue 69 in the definition of antibody-binding epitopes EDTA treatment of serum unmasks complement-mediated prozone inhibition in human leukocyte antigen antibody testing Identification of a recurrent pattern of false-positivity by Luminex HLA MHC class I single antigen bead testing Detecting donor-specific antibodies: the importance of sorting the wheat from the chaff Of cells and microparticles: assets and liabilities of HLA antibody detection 32-OR: are all anti-HLA-Cw antibodies detected with luminex single antigen bead real antibodies? Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation Practical value of identifying antibodies to cryptic HLA epitopes in cardiac transplantation. The Journal of heart and lung transplantation the official publication of the International Society for Heart Transplantation Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure Abolishing serum interference in detection of HLA antibodies: who, how, when and why? HLA diagnostics: evaluating DSA strength by titration Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression Impact of Class II invariant chain peptide (CLIP) in HLA alloantibody recognition Methods of detecting alloantibodies to HLA Class II antigens. United States Impact of peptides on the recognition of HLA Class I molecules by human HLA antibodies Perception versus reality?: Virtual crossmatch-how to overcome some of the technical and logistic limitations Physical crossmatching vs virtual crossmatching: the end of an era? or why give up a good thing? Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation Effect of influenza vaccination inducing antibody mediated rejection in solid organ transplant recipients Infectious pathogens may trigger specific allo-HLA reactivity via multiple mechanisms COVID-19 vaccines: modes of immune activation and future challenges HLAspecific B cells: I. A method for their detection, quantification, and isolation using HLA tetramers A memory B cell crossmatch assay for quantification of donor-specific memory B cells in the peripheral blood of HLA-immunized individuals Value of monitoring circulating donor-reactive memory B cells to characterize antibodymediated rejection after kidney transplantation